AI Terminal
Q-Linea
Earnings Release • May 28, 2024
3100_iss_2024-05-28_53a18532-573f-4258-80e7-5822ac5a9712.pdf
Earnings Release
Open in ViewerOpens in native device viewer
Technology behind Podler valued at SEK 70 million
Q-linea AB (publ) (OMX:QLINEA) today announces that the technology behind Podler has been valued at SEK 70 million. The valuation is based on a report carried out by an external analysis company.
In a previous press release, the Company announced that the technology behind Podler has been placed in a separate subsidiary. The valuation of the technology at SEK 70 million means that equity in the parent company Q-linea AB will be strengthened correspondingly, while equity on a group level will not be affected.
Podler is a technology that has been developed by Q-linea which enables the diagnosis of patients with blood infections to be speeded up. Today, all blood cultures need to be incubated in dedicated blood culture cabinets to be able to enrich bacteria and alert in the presence of bacteria in the blood. This enrichment step is crucial for follow-up tests such as rapid AST and ID analysis.
Today, this enrichment takes place in blood culture cabinets placed mainly in the microbiology laboratories of hospitals. This means that the samples must be transported, both within the hospital and from neighboring hospitals that do not have blood culture capacity. During transport, there is no or limited growth in the sample, which means that diagnostics does not start until the sample is loaded into the blood culture cabinet. The transport can often take over 10 hours, which can be life-threatening for patients with blood infections.
Podler can be seen as a portable blood culture cabinet and enables the initiation of sample analysis directly at the patient, resulting in large time savings.
For more information, please contact:
Stuart Gander, President & CEO, Q-linea [email protected] +1 857 409 7463
Christer Samuelsson, CFO /IR, Q-linea AB [email protected] +46 (0) 70-600 15 20
About Q-linea
Q-linea's rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.
Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.
ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com
This information is information that Q-linea is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-05- 28 08:58 CEST.